Fewer than one in 10 individuals eligible to benefit from obesity jabs such as Wegovy have access to them, warns the WHO as it publishes its initial recommendations on the medications.
With in excess of 1,000,000,000 individuals worldwide now obese, it is calling for more widespread and fairer access to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.
"Our latest guidance acknowledges that excess weight is a lifelong illness that can be addressed with comprehensive and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are significant obstacles to broad availability to the injections that can aid individuals in losing substantial body mass, notes the body.
Weight-Loss Drug Supply Crisis
Even in the present most favorable scenario, the supply of such drugs could only cover approximately 100 million people – under 10% of the global need, according to the WHO.
The recommendation calls on governments and firms to increase access, through strategies such as patent sharing.
A patent on the active ingredient – the main ingredient of a leading brand – is set to lapse in multiple countries in 2026.
The Way Obesity Injections Operate
The injections replicate a body's own hormone to delay gastric emptying, suppress the appetite and increase feelings of fullness so individuals consume fewer calories.
Individuals typically start to lose weight in the initial weeks of beginning the weekly injections.
Studies indicates people may put most of the weight back on a year later of halting the drug, as their normal hunger return.
Being carrying excess weight elevates your risk for experiencing diseases, like diabetes, heart disease, stroke, and some malignancies.
Obesity concerns individuals in every country and was responsible for over three and a half million fatalities worldwide in 2024, according to the health agency.
